• Fri news: Pfizer’s $1B Chinese commitment. RFK Jr. and pharma. Eisai dials back Leqembi forecast. US diabetes burden increase. JNJ gets Varipulse approval. See more on our front page

The VBU continues to crumble

anonymous

Guest
It’s speaks volumes about the state of the VBU when the two Senior Marketing Directors of the two largest products ( Arexvy and Shingrix) exit the company within two weeks of each other.

The “transformation” has been nothing short of a catastrophe. Quickly ruining a business that so many spent years building. Terrible decisions on people placement and business decisions. Inept senior leadership.
Look for good people to continue to leave this mess.

oh yeah, if things are not going well let’s put the blame on the VELs not on senior leadership that have demonstrated no leadership or understanding of the vaccines business.
 






It’s speaks volumes about the state of the VBU when the two Senior Marketing Directors of the two largest products ( Arexvy and Shingrix) exit the company within two weeks of each other.

The “transformation” has been nothing short of a catastrophe. Quickly ruining a business that so many spent years building. Terrible decisions on people placement and business decisions. Inept senior leadership.
Look for good people to continue to leave this mess.

oh yeah, if things are not going well let’s put the blame on the VELs not on senior leadership that have demonstrated no leadership or understanding of the vaccines business.


Let’s be honest, are we really going to miss the two marketing leads?
 




It’s speaks volumes about the state of the VBU when the two Senior Marketing Directors of the two largest products ( Arexvy and Shingrix) exit the company within two weeks of each other.

The “transformation” has been nothing short of a catastrophe. Quickly ruining a business that so many spent years building. Terrible decisions on people placement and business decisions. Inept senior leadership.
Look for good people to continue to leave this mess.

oh yeah, if things are not going well let’s put the blame on the VELs not on senior leadership that have demonstrated no leadership or understanding of the vaccines business.

Are you autistic by any chance? You have this insane focus on the VBU and gnashing your teeth about the VBU and tearing your hair out about the VBU. It's BORING man, find something else to discuss.
 








It’s speaks volumes about the state of the VBU when the two Senior Marketing Directors of the two largest products ( Arexvy and Shingrix) exit the company within two weeks of each other.

They are both experiencing a severe decline in health, most likely as a result of mandated COVID shots. Ironic, isn't it? When the cobbler's children have no shoes?
 
































It’s speaks volumes about the state of the VBU when the two Senior Marketing Directors of the two largest products ( Arexvy and Shingrix) exit the company within two weeks of each other.

The “transformation” has been nothing short of a catastrophe. Quickly ruining a business that so many spent years building. Terrible decisions on people placement and business decisions. Inept senior leadership.
Look for good people to continue to leave this mess.

oh yeah, if things are not going well let’s put the blame on the VELs not on senior leadership that have demonstrated no leadership or understanding of the vaccines business.
 




So what exactly is going on at the VBU? We are all siloed here at GSK so nobody knows what goes on outside your own division. Recent layoffs and restructuring are nothing new here. I have heard it’s a mess in vaccines now, especially when it comes to leadership. What are they doing over there?
 








So what exactly is going on at the VBU? We are all siloed here at GSK so nobody knows what goes on outside your own division. Recent layoffs and restructuring are nothing new here. I have heard it’s a mess in vaccines now, especially when it comes to leadership. What are they doing over there?
Gee, this doesn't seem like a phony question at all
 








I have an interview for the pediatric position covering portland to medford, OR. Can anyone give me insights as to why the territory is open and a general assessment of the market condition a pediatric rep would face in this territory.
 




I have an interview for the pediatric position covering portland to medford, OR. Can anyone give me insights as to why the territory is open and a general assessment of the market condition a pediatric rep would face in this territory.
A pediatric rep in this territory has to take on some pretty tough terrain. Terrain so tough you'll be asked to prove your toughness in the interview by being asked to mastvrbate into a tissue
 




That's a challenging market dominated by Sanofi. The previous representative was highly experienced and had a good tenure before leaving the position. Unless you're someone with significant experience, I'd recommend considering passing on the interview.